IL23A

(redirected from IL23P19)

IL23A

A gene on chromosome 12q13.13 that encodes interleukin-23A, a cytokine which associates with IL-12B to form IL-23, a heterodimeric cytokine involved in innate and adaptive immunity. IL-23 binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R, activates the JAK-START signalling cascade, stimulates memory T cells and promotes production of proinflammatory cytokines.
 
Molecular pathology
IL-23 may induce autoimmune inflammation and play a role in tumourigenesis.
Mentioned in ?
References in periodicals archive ?
Oral administration of resveratrol diminished the severity of imiquimod-induced psoriasis-like inflammation in an animal model, and microarray analysis revealed that resveratrol treatment inhibited imiquimod-induced expression of IL-17A, IL-19, and IL23p19. Resveratrol has been shown to inhibit LPS- and TNF-[alpha]-induced NF-[kappa]B activation [171].
However, expression of other proinflammatory cytokines such as IL-1[beta], IL-12p40, IL23p19, and IL-27, which also has regulatory functions [35], was undetectable in all samples tested (data not shown), while expression of IL-6 and IL-12p35 both in the CCC and NIC groups was similar to that found in control samples (Figure 3).
[110] found that fumarates induced type II DCs as a result of initial GSH depletion followed by induction of HO-1, which interacts with AP-1 and NF-[kappa]B sites of Il23p19 promoter and inactivates STAT1 and thereby improves [T.sub.H]1-and [T.sub.H]17-mediated AD including MS and psoriasis.